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In their conclusions, the investigators are 
quite pessimistic. Although it is important 
to be aware of shortcomings in treatment 
guidelines, Tan et al. (2010) overlook the 
high domain scores for “scope and pur-
pose,” “clarity and presentation,” and 
positive conclusions about “rigor of devel-
opment.” Not surprisingly, some of the 
guidelines lack some AGREE items. In the 
process of developing guidelines, certain 
decisions will be made that do not favor all 
the AGREE items. These might be attribut-
able to time restrictions and costs, among 
other reasonable factors. We acknowledge, 
however, that deviations from the AGREE 
instrument may be worth noting.
Living guidelines
Regular guideline updates are necessary 
to incorporate new evidence into clinical 
practice. We agree that guidelines should 
mention update procedures. In reality, 
guidelines for psoriasis should be updated 
continually, because it is likely that they 
will be outdated the moment they are pub-
lished. We stress the importance of devel-
oping “living” guidelines that can be updat-
ed as important new evidence becomes 
available. High-quality systematic reviews 
on subjects that play a role in psoriasis care 
could be incorporated in these updates, 
and recommendations should be based on 
the strength of evidence and stakeholders’ 
considerations.
International guidelines should be 
developed cooperatively and then adjusted 
for national and local use. Implementation 
is an important issue because it may be 
difficult for practitioners to choose which 
guidelines to use in daily practice.
Summary
Independent evaluation of existing pso-
riasis treatment guidelines with AGREE 
reveals areas for improvement that should 
be taken into account in future guidelines. 
Assessment of the content and quality of 
evidence used in developing such guide-
lines is the next step to be taken. 
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Clinical Implications
•  In the field of treatment guideline development, standards of quality 
are defined by the AGREE instrument.
•  Cooperation among guideline developers is important with each step in 
quality improvement, thus saving time and money. 
•  Treatment of psoriasis, although individualized with respect to patient 
needs and local options, should balance individualized treatment with 
general, evidence-based best practices.
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Circulating Tumor Cells  
and Melanoma Progression
Xiaowei Xu1 and Jiang F. Zhong2
Circulating tumor cells (CTCs) are cancer cells shed from either a primary tumor or 
its metastases that circulate in the peripheral blood. CTCs are potential seeds for 
metastases, and analyses of CTCs may allow earlier detection of metastasis-capa-
ble malignancy, monitoring for tumor recurrence, and accurate prognostication. 
Studies on CTCs have focused mainly on the detection of epithelial cancer cells. In 
this issue, De Giorgi et al. show that CTCs can be detected in melanoma patients 
using a filtration method, and that a higher percentage of patients with metastatic 
melanoma have detectable CTCs than do patients with primary melanoma.
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Circulating tumor cells (CTCs) are 
cancer cells that have detached from a 
primary tumor or its metastases and cir-
culate in the bloodstream. During tumor 
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Clinical Implications
•  Melanoma CTCs can be detected using size-based filtration.
•  CTCs appear early in melanoma progression and may be detected in 
29% of primary melanomas and 22% of lesions with a Breslow thickness 
of less than 1 mm.
•  Long-term follow-up studies using large cohorts of patients are needed 
to determine the clinical value of detecting CTCs.
progression, a subpopulation of tumor 
cells escape into lymphatic or blood 
vessels and circulate until they are either 
eliminated by host response mechanisms 
or find a micro environment in which to 
reside and to proliferate at a later time. 
The detection of CTCs in the periph-
eral blood of patients with cancer has 
important prognostic and therapeutic 
implications.
CTCs are found in frequencies on 
the order of 1–10 cells per milliliter of 
whole blood in patients with metastatic 
disease, and they are not easily detected. 
Therefore, a key to the use of CTCs as a 
biomarker is the technology designed to 
identify them in peripheral blood. The 
US Food and Drug Administration has 
approved the Veridex CellTrack Analyzer 
for monitoring therapeutic responses in 
patients with breast, prostate, and colon 
cancer. This technology relies on the 
expression of epithelial cellular adhesion 
molecules (EpCAMs) by epithelial cells 
and the isolation of these cells by immu-
nomagnetic capture using anti-EpCAM 
antibodies. Enriched CTCs are then iden-
tified by immunofluorescence. In the 
case of metastatic cancer, the pretreat-
ment presence of CTCs is prognostic of a 
poor outcome. Furthermore, in patients 
with metastatic breast cancer, the pres-
ence of CTCs after the first course of 
chemotherapy is predictive of treatment 
failure (Cristofanilli et al., 2005). The 
CTC test may therefore permit oncolo-
gists to make an early decision to dis-
continue first-line therapy for metastatic 
breast cancer in favor of more aggressive 
alternatives. This personalized treatment 
mechanism may improve the survival 
rate of all cancer patients.
Most CTC studies focus on epithelial 
cancers. De Giorgi et al. (2010, this issue) 
use a filtration method to detect and 
characterize CTCs directly in cutaneous 
melanoma patients. CTCs were detected 
and immunohistochemically verified in 
29% of patients with primary invasive 
melanoma and 63% of patients with 
metastatic melanoma. None of the con-
trols (including 10 subjects undergoing 
surgery for melanocytic nevi, 5 patients 
with non-melanoma skin tumors, and 38 
healthy volunteers) had detectable mela-
noma CTCs. In addition, CTC detection 
correlated with the presence of tyrosi-
nase mRNA in blood samples, assayed 
by real-time RT-PCR. This study demon-
strated the potential of CTCs to serve as 
diagnostic and prognostic markers for 
melanoma.
It is interesting that in this study CTCs 
were detected in 22% of melanoma 
patients with thin primary tumors (<1 
mm). We and other groups have shown 
that melanoma cells may access lym-
phatic vessels early in tumor progression; 
for example, 33% of patients with prima-
ry melanomas already have detectable 
tumor cells in the lymphatic vessels (Xu 
et al., 2008). The presence of CTCs may 
indicate melanoma progression and that 
a subpopulation of melanoma cells is 
able to gain access to the systemic circu-
lation. De Giorgi and colleagues found 
no significant correlation between CTC 
positivity and the main clinical patho-
logical parameters, including Breslow 
thickness, Clark’s level, ulceration, his-
tological subtype, and anatomical site 
in patients with primary melanoma. In 
addition, no statistically significant dif-
ference in terms of number of CTCs 
per milliliter of blood was detected in 
patients with primary invasive versus 
metastatic melanoma; this lack of cor-
relation may be attributable to the rela-
tively small sample size of this study. 
In addition, the study’s short follow-up 
period does not allow an assessment of 
the effect of CTCs on clinical outcome. 
Therefore, prospective studies with long-
term clinical follow-up in larger patient 
cohorts should be performed.
De Giorgi et al. report that in patients 
for whom both preoperative and post-
operative blood samples were available, 
24% of preoperatively negative patients 
became postoperatively positive for 
CTCs. Similar findings were noted for 
patients undergoing surgery for primary 
breast, colorectal, and prostatic cancers. 
However, these studies did not address 
whether the presence of CTCs after 
surgery was transient or persistent or 
whether the CTCs observed in the post-
operative period were capable of forming 
metastasis. Interestingly, the investigators 
also found that the intensity of immuno-
staining in CTC was often weak and less 
diffuse in comparison with melanoma 
cell lines analyzed under identical cir-
cumstances (filters). This is probably due 
to a decrease/loss in melanocytic marker 
expression, suggesting that dedifferentia-
tion may have occurred. There are many 
questions regarding the biology of CTCs; 
for example, it is unclear whether they 
are similar to the bulk of tumor cells in 
the primary site, whether they represent 
the so-called “tumor-initiating cells,” and 
whether all CTCs have similar molecular 
and biological features.
There is an urgent clinical need to 
fully characterize CTCs at the single-cell 
level. However, current biomedical tools 
are not designed for single-cell analyses, 
and material loss is the major hurdle. 
Miniaturization of these tools may be 
the solution for conducting reliable and 
cost-effective single-cell analyses in 
clinical settings. For example, iso lating 
CTCs from blood cells by flow cyto-
metric analy sis is difficult because CTCs 
are rare—estimated to be 1 among 106 
to 107 normal white blood cells (Ross 
et al., 1993). Currently, several liters of 
blood would be required for adequate 
CTC detection, a practical impossibility. 
However, by miniaturizing flow cyto metry 
machines to a nanoliter scale, several 
milliliters of blood would be sufficient for 
CTC detection. Miniaturizing PCR reac-
tors to 10-nanoliter reactors would make 
single-cell mRNA testing sufficient for 
reliable RT-PCR quantification (Zhong et 
al., 2008). Nanotechnology could bring 
single-cell analysis to reality, allowing 
the CTCs from several milliliters of blood 
to be subjected to individual molec-
ular analyses (i.e., RT-PCR), enabling 
mole cular profiles and heterogeneity of 
CTCs to be characterized.
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The work by De Giorgi and col-
leagues (2010) imparts important 
insights into melanoma biology. The 
investigators provide evidence that 
melanoma CTCs are present early 
in melanoma progression and that 
their numbers increase significantly 
in metastatic melanomas. The work 
encourages the creation of studies to 
address whether melanoma CTCs are 
a prognostic marker, whether they are 
predictive biomarkers posttherapy, and 
whether they can be used to stratify 
patients for clinical therapies.
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